Use of On-Site Testing for Drugs of Abuse. Use of On-Site Testing for Drugs of Abuse.

Use of On-Site Testing for Drugs of Abuse‪.‬

Clinical Chemistry 2002, Oct, 48, 10

    • $5.99
    • $5.99

Publisher Description

The use of on-site or near-patient testing (NPT) [1] devices as an aid in clinical diagnosis has long been recognized as a mechanism to allow rapid generation of biomedical results. NPT devices can be defined as any method that can be used to analyze specimens outside on the laboratory setting (1). The simplest of such devices are the dipstick tests and meters used in clinics and for routine measurement of chemistry analytes, ranging from the breath analyzers used at the roadside and in clinics to determine alcohol intoxication to the current spate of dipstick and cartridge tests for drugs-of-abuse screening. All of these NPT devices are classed by the Medical Devices Agency (an Executive Agency of the United Kingdom Department of Health that ensures that medical devices meet appropriate standards of safety, quality, and performance and comply with relevant Directives of the European Union) as in vitro diagnostic medical devices, defined under the In Vitro Diagnostic Medical Devices Directive 98/79/EC as "any medical device which is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment or system, whether used alone or in combination, intended by the manufacturer to be used in vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information:

GENRE
Science & Nature
RELEASED
2002
October 1
LANGUAGE
EN
English
LENGTH
23
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
175.6
KB
An Introduction to Testing for Drugs of Abuse An Introduction to Testing for Drugs of Abuse
2022
Therapeutic Drug Monitoring in Special Populations (Tdm Conference) Therapeutic Drug Monitoring in Special Populations (Tdm Conference)
1998
Analytical Chemistry for Assessing Medication Adherence Analytical Chemistry for Assessing Medication Adherence
2016
The Role of the Study Director in Nonclinical Studies The Role of the Study Director in Nonclinical Studies
2014
Laboratory-Related Outcomes in Healthcare (Beckman Conference) (Clinical Report) Laboratory-Related Outcomes in Healthcare (Beckman Conference) (Clinical Report)
2001
Illicit Drugs in the Environment Illicit Drugs in the Environment
2011
Doping in Sport: Misuse, Analytical Tests, And Legal Aspects (Editorial) Doping in Sport: Misuse, Analytical Tests, And Legal Aspects (Editorial)
1997
Vitamin E and Coronary Heart Disease in Tunisians (Nutrition) (Clinical Report) Vitamin E and Coronary Heart Disease in Tunisians (Nutrition) (Clinical Report)
2000
Endothelial Nitric Oxide Synthase Haplotypes Are Associated with Features of Metabolic Syndrome (Endocrinology and Metabolism) (Survey) Endothelial Nitric Oxide Synthase Haplotypes Are Associated with Features of Metabolic Syndrome (Endocrinology and Metabolism) (Survey)
2007
Alanine Aminotransferase As an Independent Predictor of Incident Nonalcoholic Fatty Liver Disease (Letters) (Letter to the Editor) Alanine Aminotransferase As an Independent Predictor of Incident Nonalcoholic Fatty Liver Disease (Letters) (Letter to the Editor)
2007
T-Cell Regulatory Gene CTLA-4 Polymorphism/Haplotype Association with Autoimmune Pancreatitis (Clinical Immunology) T-Cell Regulatory Gene CTLA-4 Polymorphism/Haplotype Association with Autoimmune Pancreatitis (Clinical Immunology)
2007
Percent Free Prostate-Specific Antigen in Assessing the Probability of Prostate Cancer Under Optimal Analytical Conditions (Enzymes and Protein Markers) Percent Free Prostate-Specific Antigen in Assessing the Probability of Prostate Cancer Under Optimal Analytical Conditions (Enzymes and Protein Markers)
1998